Skip to content

Study · Not a test of the peptide alone · 1995

5 results

Structure-activity studies on the vasoactive intestinal peptide pharmacophore. 1. Analogs of tyrosine.

Bolin DR, Cottrell J, Garippa R, Michalewsky J, Rinaldi N, Simko B, O'Donnell M

International journal of peptide and protein research1 Sept 1995Cited by 7 (Europe PMC)

PMID8537181 (opens in a new tab)DOI10.1111/j.1399-3011.1995.tb00599.x (opens in a new tab)PepBankPUB-08537181
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Activity measurement

    In guinea pigs, compound 43 was an active bronchodilator with slightly over 2-fold higher potency and a longer duration of action than the parent analog.

    In plain wordsIn guinea pigs, a modified VIP compound opened the airways with higher potency and longer action than the parent compound.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseBronchodilator activity of compound 43
    Study

    guinea pign: not reported in source

    Comparator
    Parent analog
    Outcome group
    Receptor activity and mechanism · Respiratory

    Measurements

    Duration of action, compound 43
    > 20 min
    guinea pig
    Duration of action, parent compound
    5 min
    guinea pig

    Source sentences

    Summary
    Compound 43 was also found to be active as a bronchodilator in vivo in guinea pigs, with slightly over 2-fold enhanced potency and a significantly longer duration of action (> 20 min) when compared to the parent compound (5 min).
    1 context sentence
    Summary · context
    Several Boc-substituted-phenylalanine derivatives were prepared and incorporated into VIP analogs as replacement for tyrosine22. These analogs, of the form Ac-[Lys12,Nle17,X22,Val26,Thr28]-VIP, were assayed as smooth muscle relaxants and found to be full agonists of native VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    In smooth muscle relaxation assays, VIP analogs with substituted phenylalanine in place of Tyr22 were full agonists of native VIP.

    In plain wordsIn lab tests, modified VIP compounds relaxed smooth muscle as fully as natural VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableAgonist activity of Tyr22-substituted VIP analogs
    Study

    n: not reported in source

    Comparator
    Native VIP
    Outcome group
    Receptor activity and mechanism · Respiratory

    Source sentences

    Summary
    were assayed as smooth muscle relaxants and found to be full agonists of native VIP
    1 context sentence
    Summary · context
    Several Boc-substituted-phenylalanine derivatives were prepared and incorporated into VIP analogs as replacement for tyrosine22. These analogs, of the form Ac-[Lys12,Nle17,X22,Val26,Thr28]-VIP, were assayed as smooth muscle relaxants and found to be full agonists of native VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    Most Tyr22-substituted VIP analogs were less potent than the parent analog, by up to 300-fold.

    In plain wordsIn lab tests, most modified VIP compounds were weaker than the parent compound, by up to 300 times.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseRelative potency of most Tyr22 analogs
    Study

    n: not reported in source

    Comparator
    Parent analog
    Outcome group
    Receptor activity and mechanism · Respiratory

    Measurements

    Potency decrease versus parent analog
    ≤ 300 fold
    most analogs

    Source sentences

    Summary
    Most of the analogs, however, proved to be less potent than the parent analog by up to 300-fold.
    1 context sentence
    Summary · context
    Several Boc-substituted-phenylalanine derivatives were prepared and incorporated into VIP analogs as replacement for tyrosine22. These analogs, of the form Ac-[Lys12,Nle17,X22,Val26,Thr28]-VIP, were assayed as smooth muscle relaxants and found to be full agonists of native VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  4. 04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    A few Tyr22-substituted VIP analogs, all with electron-donating substituents, kept nearly full potency.

    In plain wordsIn lab tests, a few modified VIP compounds kept nearly full potency.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePotency of analogs with electron-donating substituents
    Study

    n: not reported in source

    Comparator
    Parent analog
    Outcome group
    Receptor activity and mechanism · Respiratory

    Source sentences

    Summary
    A few analogs, all possessing electron-donating substituents, retained nearly full potency.
    1 context sentence
    Summary · context
    Several Boc-substituted-phenylalanine derivatives were prepared and incorporated into VIP analogs as replacement for tyrosine22. These analogs, of the form Ac-[Lys12,Nle17,X22,Val26,Thr28]-VIP, were assayed as smooth muscle relaxants and found to be full agonists of native VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  5. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueActivity measurement

    Two Tyr22 analogs (3-F,4-OH-Phe and 3-OCH3,4-OH-Phe) were more potent than the parent analog and than native VIP.

    In plain wordsIn lab tests, two modified VIP compounds were more potent than the parent compound and than natural VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePotency of compounds 42 and 43 versus parent and native VIP
    Study

    n: not reported in source

    Comparator
    Parent analog and native VIP
    Outcome group
    Receptor activity and mechanism · Respiratory

    Measurements

    Potency versus parent, compound 42
    1.5 fold
    3-F,4-OH-Phe
    Potency versus parent, compound 43
    3.4 fold
    3-OCH3,4-OH-Phe
    Potency versus native VIP, compound 42
    8.9 fold
    3-F,4-OH-Phe
    Potency versus native VIP, compound 43
    20 fold
    3-OCH3,4-OH-Phe

    Source sentences

    Summary
    Two compounds, 3-F,4-OH-Phe, 42 and 3-OCH3,4-OH-Phe, 43, were found to be 1.5- and 3.4-fold more potent than the parent compound, which equates to being 8.9- and 20-fold more potent than native VIP.
    1 context sentence
    Summary · context
    Several Boc-substituted-phenylalanine derivatives were prepared and incorporated into VIP analogs as replacement for tyrosine22. These analogs, of the form Ac-[Lys12,Nle17,X22,Val26,Thr28]-VIP, were assayed as smooth muscle relaxants and found to be full agonists of native VIP.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.